Publisher
Springer Science and Business Media LLC
Reference33 articles.
1. Didato G, Di Giacomo R, Rosa GJ et al (2020) Restless legs syndrome across the lifespan: symptoms, pathophysiology, management and daily life impact of the different patterns of disease presentation. Int J Environ Res Public Health 17(10):3658
2. Allen RP, Adler CH, Du W, Butcher A, Bregman DB, Earley CJ (2011) Clinical efficacy and safety of IV ferric carboxymaltose (FCM) treatment of RLS: a multi-centred, placebo-controlled preliminary clinical trial. Sleep Med 12(9):906–913
3. DelRosso LM, Ferri R, Allen RP et al (2020) 1001 intravenous ferric carboxymaltose for restless legs syndrome in children and adolescents. Sleep 43(1):A380
4. DelRosso LM, Picchietti DL, Ferri R (2020) Comparison between oral ferrous sulfate and intravenous ferric carboxymaltose in children with restless sleep disorder. Sleep 2020:zsaa155
5. Zoller H, Schaefer B, Glodny B (2017) Iron-induced hypophosphatemia: an emerging complication. Curr Opin Nephrol Hypertens 26(4):266–275